Furthermore, PLX5562 treatment reduced ataxia at d18 and d21 post ablation (Fig. 5f) and reduced type 1 interferon-mediated neuroinflammation at d10 post ablation, as measured by expression of Oas1a and mx1 at d10 post DT (Fig. 5g). The gene discussed is MX1; the disease is Ataxia.